The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia
Abstract
To investigate the lipoprotein effect of fenofibrate in hypercholesterolemia or combined hyperlipidemia (types II A and II B hyperlipidemias, respectively), 240 patients were recruited and 227 randomized to a double-blind randomized trial lasting 24 weeks and 192 patients continued to participate in an open-label phase for another 24 weeks. A 100-mg dose of fenofibrate or a matching placebo was given three times daily. Fenofibrate side effects in excess of placebo affected 6 percent of fenofibrate users and were confined almost entirely to skin rashes. In 180 hypercholesterolemic patients randomly assigned to receive fenofibrate versus placebo, triglyceride and very low-density lipoprotein cholesterol levels decreased 38 percent, total cholesterol levels decreased 17.5 percent, and low-density lipoprotein cholesterol levels decreased 20.3 percent with fenofibrate treatment. High-density lipoprotein cholesterol levels increased 11.1 percent with a decrease in the low-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratio of 27 percent. All differences were statistically significant (p less than 0.01). In combined hyperlipidemic (type II B) patients, triglyceride levels decreased by 45 percent, very low-density lipoprotein cholesterol levels decreased 52.7 percent, total cholesterol levels decreased 16 percent, low-density lipoprotein cholesterol levels decreased 6 percent, and high-density lipoprotein levels increased 15.3 percent for a low-density lipopro…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fenofibrate can lower LDL-C by 15–20% in patients with high baseline levels who do not have concomitant hypertriglyceridaemia.45”
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Faggiotto, A., Ross, R., & Harker, L. (1984) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.4.4.323 · Cited by 984
Faggiotto, A., & Ross, R. (1984) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.4.4.341 · Cited by 465
Metabolic relationships among the plasma lipoproteins
Wilson, D. E., & Lees, R. S. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106896 · Cited by 291
Eisenberg, S., Gavish, D., Oschry, Y., Fainaru, M., & Deckelbaum, R. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111444 · Cited by 284
Iman, R. L. (1974) · Canadian Journal of Statistics · doi:10.2307/3314695 · Cited by 116
Brown, W., Dujovne, C., Farquhar, J., Feldman, E. B., Grundy, S., Knopp, R. H., Lasser, N., Mellies, M., Palmer, R., & Samuel, P. (1986) · Arteriosclerosis · doi:10.1161/01.atv.6.6.670 · Cited by 92
Self-citation
Research works printed but not linked: 8
- Baker, 1982, Evaluation a long terme de l'activite hypolipidemiante et de la tolerance du fenofibrate, Prog Med, 110, 18
- Wulfert, 1982, Efficacy and tolerance of fenofibrate: a review of clinical experience, 87, 91
- Drouin, 1979, The effect of fenofibrate (procetofen) on the lipoprotein profile in patients affected by primary type II hyperlipoproteinemia, Curr Ther Res, 26, 350
- Lehtonen, 1981, Effet of procetofen on serum total cholesterol, triglyceride, and high density lipoprotein cholesterol concentrations in hyperlipoproteinemia, Int J Clin Pharmacol Ther Toxicol, 19, 534
- Michell, 1979, Treatment of hyperlipoproteinemia (HLP) type IIa with a new phenoxyisobuturic acid derivative, procetofen, Int J Clin Pharmacol Biopharm, 17, 503
- Vega G, Grundy SM: Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. JAMA 253; 2398-2403. · doi:10.1001/jama.1985.03350400082026
- Schwartzkopff, 1982, Untersuchungen zur Wirksamkeit von Bezafibrat und Fenofibrat auf erhehte Lipide des Blutes beim HLP Type IIa, IIb, und IV, Med Welt, 33, 631
- Bissonette, 1983, Use of gemfibrozil in patients with dyslipidemia: a double-blind comparison with placebo, Int Med for the Spec, 9, 132
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
“baseline levels who do not have concomitant hypertriglyceridaemia.(45) This fibrate is easy to take, and has shown an excellent safety record in the Action to Control Cardiovascular Risk in Diabetes”
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Self-citationPeriodontitis and Diabetes Interrelationships: Role of Inflammation
Iacopino, A. M. (2001) · Annals of Periodontology · doi:10.1902/annals.2001.6.1.125 · Cited by 393
Lipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354
“These agents are effective in reducing plasma triglyceride concentrations and modestly increasing HDL cholesterol concentrations in the general population (115,116).”
BackgroundBalfour, J. A., McTavish, D., & Heel, R. C. (1990) · Drugs · doi:10.2165/00003495-199040020-00007 · Cited by 204
Metadata
- Authors
- Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., Samuel, P., Schonfeld, G., & Superko, H. R.
- Affiliations
- University of Washington (US)
- Corresponding author
- Knopp, Robert H.
- ORCID
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1987-11
- Volume
- 83
- Issue
- 5
- Pages
- 50-59
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2106189850
- Cited by
- 65
- References
- 21
- Citations by year
- 2023: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 2
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (3p30am030865-04s1, 1p30am035816-01)
- National Heart, Lung, and Blood Institute (HL3-0086)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- hypercholesterolemia, mixed dyslipidemia, type II hyperlipidemia, serum lipoproteins, triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol, fibrates, drug tolerability, hypertriglyceridemia
- MeSH terms
- Adult, Aged, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Hyperlipidemias, Lipoproteins, Male, Middle Aged, Fenofibrate, Propionates, Random Allocation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. https://app.cochat.ai/papers/10.1016/0002-9343(87)90871-0
- The paper
- Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., Samuel, P., Schonfeld, G., & Superko, H. R. (1987). Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. The American Journal of Medicine. https://doi.org/10.1016/0002-9343(87)90871-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.